Skip to content
NewsBlazeAU – Lifestyle
Author:
Riboscience LLC
Riboscience to Present First Overall Survival and Immune Activation Data from Phase 1b Study of ENPP1 Inhibitor RBS2418 as Monotherapy and in Combination in Advanced Metastatic Cancers Including MSS CRC, at ESMO 2026
October 19, 2026